Correspondence 0001104659-24-004285 from Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635) (RNAZ)
Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635)
Date: Jan. 17, 2024 · CIK: 0001829635 · Accession: 0001104659-24-004285
AI Filing Summary & Sentiment
File numbers found in text: 333-276467
Letter
VIA EDGAR Attention: Mr. Tim Buchmiller Acceleration Request for Registration Statement on Form S-1, as amended File No. 333-276467
Re: TransCode Therapeutics, Inc.
Dear Mr. Buchmiller:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), TransCode Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to January 17, 2023, at 5:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Finn Murphy at (212) 459-7257.
Please contact Michael Bison and Finnbarr Murphy of Goodwin Procter LLP via telephone at (617) 570-1933 and (212) 459-7257 or via e-mail (MBison@goodwinlaw.com or FMurphy@goodwinlaw.com), respectively, with any questions.
Sincerely,
TRANSCODE THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
January 17, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549-3233
Attention: Mr. Tim Buchmiller
Re: TransCode Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-1,
as amended
File No. 333-276467
Dear Mr. Buchmiller:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended (the “Act”), TransCode Therapeutics, Inc. (the “Company”) hereby requests
that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated
to January 17, 2023, at 5:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin
Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration
request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once
the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Finn Murphy
at (212) 459-7257.
Please contact Michael Bison and Finnbarr Murphy
of Goodwin Procter LLP via telephone at (617) 570-1933 and (212) 459-7257 or via e-mail (MBison@goodwinlaw.com or FMurphy@goodwinlaw.com),
respectively, with any questions.
Sincerely,
TRANSCODE THERAPEUTICS, INC.
/s/ Thomas Fitzgerald
Thomas Fitzgerald
Interim Chief Executive Officer
cc:
Michael Bison, Goodwin Procter LLP
Finn Murphy, Goodwin Procter LLP